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Abstract
The ability to regulate the cellular homeostasis of a higher
organism through tight control of apoptosis and cell
division is crucial for life. Dysregulation of these mecha-
nisms is often associated with cancerous phenotypes in
cells. Optimal cancer therapy is a fine balance between
effective cancer cell killing and at the same time minimiz-
ing, or avoiding, damage to the surrounding healthy tissue.
To obtain this, it is necessary to identify and inhibit
molecular targets on which the cancer cells are strongly
dependent. Survivin represents such a target, and it
has been published previously that peptide vaccines, the
small-molecule YM155, and the antisense molecule
LY2181308/ISIS23722, via different mechanisms, have
been used as survivin inhibitors. In this article, a new
potent antisense inhibitor of survivin, SPC3042, is pre-
sented, and the properties of SPC3042 are compared with
the previously published antisense drug, LY2181308/
ISIS23722. SPC3042 is a 16-mer locked nucleic acid
(LNA) oligonucleotide and designed as a fully phosphor-
othiolated gapmer containing 7 LNA nucleotides in the
flanks. The LNA nucleotides in SPC3042 provide nuclease
stability and higher potency for survivin mRNA inhibition
compared with earlier generations of antisense reagents.
It is shown that the down-regulation of survivin with
SPC3042 leads to cell cycle arrest, pronounced cellular
apoptosis, and down-regulation of Bcl-2. It is also shown
that SPC3042 is a sensitizer of prostate cancer cells to
Taxol treatment in vitro and in vivo. [Mol Cancer Ther
2008;7(9):2736–45]
Introduction
Survivin is a 17-kDa protein and a key regulator of
apoptosis and cell cycle progression (1, 2). Survivin plays
a dual biological function, as it protects cells from apoptosis
downstream of the intrinsic apoptotic pathway, and is
involved in regulation of mitosis (1, 2), as the protein
selectively accumulates and localizes to various compo-
nents of the mitotic apparatus during the mitotic spindle
formation. Despite this dual role, survivin has been
classified to belong to the family of inhibitors of apoptosis
proteins (IAP), which also include the human members
XIAP, cIAP1, cIAP2, NIAP, ML-IAP, and apollon. These are
characterized by the presence of baculovirus IAP repeat
domains and are able to interfere with regulation of
apoptosis through either direct or indirect interaction
with caspases (pro-caspase-9, caspase-3, and caspase-7;
refs. 3–5). Survivin is characterized by the presence of only
one baculovirus IAP repeat domain and the lack of a RING
finger domain present in other IAPs. The central role of
survivin in cell cycle regulation, where it forms a complex
with the inner centromere protein and Aurora-B kinase to
promote chromosome segregation and cytokinesis in the
Gap2 mitosis (G2-M) phase of the cell cycle, has been
shown in several publications (6–8).
Survivin is abundantly expressed during embryonic
development and plays an important role in the controlled
cell divisions of normal growth and tissue differentiation.
In adult healthy tissues, survivin plays a more reduced role
and is only expressed in thymocytes (9), basal colonic
epithelium (9), endothelial cells (9), CD45+ bone marrow-
derived stem cells (9), and endometrial cells (9).
However, during carcinogenesis, survivin is often acti-
vated and can play a key role in aberrantly controlled cell
division. It therefore becomes important for generating and
maintaining the malignant phenotype. Furthermore, ex-
pression of survivin in tumor tissue is found to be closely
linked with a poor prognosis in several cancers [e.g.,
colorectal cancer (10, 11), acute myeloid leukemia (12), and
prostate cancer (13, 14)].
Because survivin is almost exclusively expressed in
cancer cells, it is regarded as one of the most cancer-
specific targets, and inhibition of survivin expression has
therefore been of interest for its anticipated valuable
therapeutic outcomes for many years.
Oligonucleotide-based approaches targeting survivin
mRNA by either small interfering RNA (15–18) or
antisense oligonucleotides (19–22) are important rational
strategies to silence its expression. Small interfering RNAs
are potent inhibitors in vitro but cannot be used directly
in vivo due to their low nuclease resistance and the lack
of cellular uptake. However, chemically modified single-
stranded oligonucleotides are taken up by cells in vivo and
thus offer a therapeutic platform.
Previously, the most frequently used chemical modifica-
tion was phosphorothioates in which one oxygen of the
internucleoside phosphate is replaced with sulfur. Today,
the phosphorothioate modification is used in combination
with other chemical modifications (23). Classic chemical
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modifications are the ‘‘2¶ modifications’’. Examples of this
class are 2¶-O -Me and 2¶-O -methoxyethyl (MOE). A
representative of the latter is the antisense drug
LY2181308/ISIS23722 (1, 19, 24, 25), which is currently
being tested in a phase II trial for treatment of hepatocel-
lular carcinoma.
Locked nucleic acids (LNA) represent a new class of
antisense oligonucleotides. In the LNA nucleoside,
the furanose is chemically modified by the insertion of
a 2¶-O-CH2-4¶ linkage that transforms the furanose to a
bicyclic structure. The bicyclic structure of LNA nucleo-
sides locks the ribose conformation leading to an
unprecedented high nucleic acid affinity of oligonucleo-
tides comprising LNA nucleosides. The LNA modification
substantially improves nuclease resistance, permits reduc-
tion in length, and maintain the affinity in combination
with PS. LNA oligonucleotides are frequently used for
antisense (26–30) and 14- to 16-mer LNAs typically have
IC50 values, in classic cell-based assays, in the low to
subnanomolar range, thus exhibiting similar potencies to
small interfering RNA (31).
In this study, we report the properties of SPC3042. The
compound is designed as an antisense 16-mer LNA gapmer
targeting the region comprising the stop codon of the open
reading frame in exon 4 of the survivin transcript. We
compare the antisense properties of SPC3042 with
ISIS23722, an oligonucleotide that targets the 3¶-untranslat-
ed region of the survivin transcript and SPC2822, which has
an identical sequence to ISIS23722 but where the 2¶-O-MOE
nucleotides are replaced with LNA nucleotides. The
sequence of SPC3042 is also prepared as the ‘‘3042MOE,’’
in which the LNA nucleotides are replaced with 2¶-O-MOE
nucleotides.
Materials andMethods
Oligonucleotides andThermalDenaturationMeasure-
ments
LNA oligonucleotides were synthesized according to
methods described by Frieden et al. (32) The 2¶-O-MOE
amidites were prepared according to published procedures
(33, 34), except for the final phosphorylation step that was
done according to Pedersen et al. (35).
Oligonucleotides were synthesized using the phosphor-
amidite approach on an Expedite 8900/Multiple Oligonu-
cleotide Synthesis System synthesizer at a 1 Amol scale. At
the end of the synthesis, the oligonucleotides were cleaved
from the universal solid support using aqueous ammonia
for 1 to 2 h at room temperature and further deprotected for
4 h at 65jC. The oligonucleotides were purified by reverse-
phase high-performance liquid chromatography and were
then characterized by liquid chromatography-mass spec-
trometry (reverse phase and electrospray ionization-mass
spectrometry).
The melting temperature of oligonucleotide/RNA
duplexes was determined by using UV spectrometry.
Duplexes of oligonucleotide and cRNA oligonucleotide
(1.5 Amol/L concentration) were prepared in thermal
denaturation (Tm) buffer [100 nmol/L NaCl, 0.1 nmol/L
EDTA, 10 mmol/L NaP (pH 7.0)] for analysis by heating to
95jC for 3 min and cooled at room temperature for 30 min.
Melting temperature (Tm) values were measured in a
Lambda 40 UV-visible spectrophotometer (Perkin-Elmer)
and data were collected and analyzed using TempLab
software (Perkin-Elmer). The instrument was programmed
to heat the oligonucleotide duplex sample from 20jC to
95jC and afterwards to cool the sample to 25jC. During
this process, the absorbance at 260 nm was recorded. The
melting curves were used to calculate Tm values.
Nuclease Stability
Mouse or human plasma was defrosted and part of the
sample was preincubated for 24 h at 37jC before assaying;
to 45 AL plasma from stock solution (not preincubated) was
added 5 AL oligonucleotide to a final concentration of
20 Amol/L. Samples were incubated at 37jC for 0 to 72 h.
At different time points, samples were collected and ‘‘snap
frozen’’ in liquid N2 before storage at 80jC. When all
samples were collected, they were analyzed by electropho-
resis on PAGE gels (16%; 8 mol/L urea).
Cell Culturing
The prostate cancer cell line 15PC3 was used in all in vitro
studies (kindly provided by Dr. F. Baas, Neurozintuigen
Laboratory). Cells were kept as frozen stocks, thawed, and
grown in DMEM (Sigma) plus 10% fetal bovine serum
(Biochrom), 1% GlutaMAX I 100 (Invitrogen), and 0.05%
gentamicin (Sigma) at 37jC in 5% CO2.
Transfection
Cells were seeded 2 days before transfection in T75 flasks
or 12-well plates (Nunc) at a density of 0.8  106 or 0.9 
105 per flask or well, respectively. At 60% to 70%
confluence, cells were transfected with oligonucleotides at
final concentrations varying from 0.04 to 25 nmol/L. In
mock transfections, sterile water was used instead of
oligonucleotide. At the time of transfection, the cells were
washed in Dulbecco’s PBS (Sigma) followed by addition of
5 Ag/mL LipofectAMINE 2000 (Invitrogen) in Opti-MEM I
+ GlutaMAX I (Life Technologies). The cells were incubated
for 7 min at room temperature. Oligonucleotides at varying
concentrations dissolved in Opti-MEM I + GlutaMAX I
were added and the cells were incubated for 4 h. The
cells were washed in PBS, fresh medium was added, and
cells were incubated until harvested.
Cells were harvested after 24, 48, or 72 h by washing in
PBS and trypsinizing, which was quenched with culture
medium. The cells were collected in 15 or 50 mL tubes by
centrifugation. Cell pellets were washed in PBS and
separated for further analysis.
Propidium Iodide Staining
Transfected cells were harvested as described above and
washed twice in PBS. Approximately 106 cells were fixed in
ice-cold ethanol (70%) for 30 min at 4jC. The fixed cells
were washed twice in PBS to remove all ethanol. A nuclear
staining solution [33 Ag/mL propidium iodide, 1 mg/mL
RNase A (Sigma) in PBS] was then added. The cells were
incubated in the dark at room temperature for 30 min and
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analyzed by flow cytometry using a FACSCalibur (Becton
Dickinson). Fluorescence intensity was measured and
plotted against cell count.
Total RNAPurification
Total RNA was isolated from transfected cells using the
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
recommendations. The total RNA concentration was
measured by UV spectroscopy at 260 nm. The ratio of
260/280 nm was used as a measure of RNA purity. Isolated
RNA was stored at 80jC.
cDNASynthesis
First-strand cDNA was synthesized from 0.5 Ag total
RNA using OmniScript Reverse Transcriptase kit (Qiagen)
according to the protocol provided by the manufacturer.
Quantitative PCR
The relative amounts of total survivin mRNA in trans-
fected cells were measured by quantitative PCR using
primers amplifying a 121-bp fragment of survivin exon 1.
Template cDNA was diluted 5-fold before mixing with a
Platinum Quantitative PCR SuperMix uracil DNA glyco-
sylase (Invitrogen) and a primer-probe mix containing
0.6 Amol/L forward primer (5 ¶-AAGGACCACCG-
CATCTCTACA-3¶), 0.9 Amol/L reverse primer (5¶-
CCAAGTCTGGCTCGTTCTCAGT-3¶), and 0.1 Amol/L
probe (5 ¶-FAM-GAGGCTGGCTTCATCCACTGCC-
TAMRA-3¶) according to manufacturer’s protocol.
A commercially available human glyceraldehyde
3-phosphate dehydrogenase (20) primer-probe mix
(Applied Biosystems) was used for glyceraldehyde
3-phosphate dehydrogenase measurements. For human
Bcl-2 mRNA, a 20 primer-probe mix containing 0.3
Amol/L forward primer (5¶-CATGTGTGTGGAGAGCGT-
CAA-3¶), 0.6 Amol/L reverse primer (5¶-GCCGGTTCAGG-
TACTCAGTCA-3¶), and 0.1 Amol/L TaqMan probe
(5¶-FAM-CCTGGTGGACAACATCGCCCTGT-TAMRA-3¶)
was used.
Quantitative PCR was done on an iCycler instrument
(Bio-Rad) using 50jC for 2 min, 95jC for 5 min followed by
40 cycles of 95jC for 30 s and 60jC for 1 min.
Data obtained from quantitative PCR analysis were
analyzed using the iCycler iQ Real-time Detection System
software (Bio-Rad). Data were correlated to a cDNA
standard curve made from nontransfected 15PC3 cells.
The survivin mRNA level was normalized to glyceralde-
hyde 3-phosphate dehydrogenase mRNA levels and
plotted relative to an average value of the mock samples
from the same transfection, which was set to 100%.
Survivin Protein Detection-ELISA
Survivin protein levels were detected by ELISA using a
DuoSet IC Human Total Survivin kit (R&D Systems).
Harvested cells were lysed in a solution consisting of PBS
added 1mmol/L EDTA, 0.5% Triton X-100 (Sigma), 6mol/L
urea (Sigma), and protease inhibitors. Total protein was
measured by BCA protein assay kit (Pierce) using an
albumin standard according to manufacturer’s protocol.
The ELISA was carried out as described in manufacturer’s
protocol using 100 AL of a 45 dilution of each lysed sample.
Survivin protein concentrations were detected by spectro-
photometer at 450/540 nm correlated to a 2-fold serial
standard dilution. Data were normalized to total amount of
protein and plotted relative to an average value of mock
samples from same transfection, which was set to 100%.
Caspase-3/7 Activity
The activity of caspase-3 and -7 was measured using a
luminogenic Caspase-Glo-3/7 substrate assay (Promega).
15PC3 cells were seeded to a density of 12,000 per well in
white 96-well plates (Nunc) in growth medium 1 day
before transfection (see above). Cells were transfected as
described above. Camptothecin (1 Amol/L; Sigma) was
used as positive control. A serial dilution of cell density
was added 200 nmol/L staurosporine (Sigma) as a control
of assay viability.
At 24, 48, or 72 h after transfection, Caspase-Glo-3/7
reagent was added to the medium and the cells were
incubated for additional 1 h at room temperature. The
activity of the caspases was measured as relative light units
per second in a Luminoscan Ascent instrument (Thermo
Labsystems). Data were correlated, plotted, and normal-
ized to an average value of the mock samples. Data from
the staurosporine-treated serial dilution were plotted and
evaluated for linearity.
PC3 Xenograft Model and Statistics
PC3 prostate cancer cells were cultured as described
above for 15PC3 cells. PC3 cells (3  106 per tumor) were
mixed with 300 AL Matrigel (Becton Dickinson) and
injected s.c. in the flank of female 8- to 10-week-old
BALB/c nu/nu mice (Taconics). The group size was 5, 8,
or 10 mice per group depending on the experiment. Saline
or drug dissolved in saline (0.9%) was injected i.p. in the
mice. The animals were observed daily for any reactions
related to the treatment or any deviations from normal
health. The day of cell implantation was designated day 0.
Tumor volume was calculated for each animal based on
tumor length and width measurement, assuming spherical
growth. At sacrifice, the tumors, livers, and spleens were
excised and weighed. The data from each mouse in each
experiment were normalized relative to the mean of the
saline control group.
Statistical analysis was done using the nonparametric
Kruskal-Wallis test with Dunn’s Multiple Comparison
post-test using GraphPad Prism 4 software.
Results
Thermal Denaturation
The Tm of the oligonucleotides (Fig. 1) was determined
against their cRNA sequences. SPC3042 gave rise to the
highest Tm of all the tested duplexes, whereas the Tm of the
corresponding 2¶-O-MOE gapmer (‘‘3042MOE’’) was 59jC.
The Tm of the unmodified 18-mer phosphorothioate
(SPC2823), isosequential with ISIS23722, was only 44jC,
whereas the Tm of ISIS23722 was 51jC. Thus, the eight
2¶-O -MOE nucleotides increase the Tm by 7jC, but
substituting the 2¶-O-MOE nucleotides with LNA residues
resulted in a increase of 19jC. The scrambled control did
not show any Tm (Fig. 1).
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SurvivinmRNA Inhibition
All oligonucleotides were transfected into the prostate
cancer cell line 15PC3 at concentrations of 1, 5, 12.5, 25,
100, and 250 nmol/L. After 4 h, the cells were transferred
to growth medium and cultured for 24, 48, or 72 h,
respectively. Survivin mRNA expression was measured
by quantitative PCR and normalized to glyceraldehyde 3-
phosphate dehydrogenase mRNA levels. The approximate
IC50 values of each oligonucleotide at the different time
points are shown in Fig. 1. The IC50 of SPC3042 at 72 h was
not possible to determine due to pronounced cellular
apoptosis, but significant survivin down-regulation could
be detected after 72 h for both SPC2822 and ISIS23722,
with IC50 values of 1 and 10 nmol/L, respectively.
Increased potency followed increased affinity (Tm) when
compared with the identical sequence. SPC3042 is more
potent than MOE3042, and SPC2822 is more potent than
ISIS23722, which is more potent than SPC2823. However,
among the sequences, a higher Tm is not necessarily
associated with higher potency (e.g., SPC3042 versus
SPC2822). The maximum potency for all oligonucleotides
was found after 24 h (Fig. 2). At low concentrations,
SPC2822 was found to be the most potent, but SPC3042
was found to be the most effective to inhibit survivin at
higher concentrations (100 and 250 nmol/L; Fig. 2); in fact,
SPC3042 was the only oligonucleotide capable of >95%
inhibition of survivin. The scrambled control SPC3046
showed no significant survivin mRNA down-regulation at
any time point (Figs. 1 and 2). The results were confirmed
by measuring the protein level using a survivin-specific
ELISA (Table 1).
Nuclease Stability
We assessed the in vitro plasma nuclease stability of the
oligonucleotides to evaluate if the antisense activity in the
cellular assay was related to differences in nuclease
resistance. The oligonucleotides were incubated in mouse
plasma for 1, 2, 4, 24, 48, and 72 h. As shown in Fig. 1, both
2¶-O-MOE and LNA nucleotides almost entirely protect
SPC3042, ISIS23722, SPC2822, and 3042MOE against nucle-
olytic degradation. However, the SPC2823 (18-mer phos-
phorothioate) is degraded more rapidly, with a half-life of
approximately 24 h. The oligonucleotides were also tested
in human plasma and the same patterns were found (data
not shown).
Apoptosis
The significance of survivin in the intrinsic apoptotic
pathway has been described (36), and a clear correlation
between survivin inhibition and induction of apoptosis in
prostate cancer cells has been documented (37). We wanted
to determine if this also was the case in 15PC3 cells.
Accordingly, we followed induction of apoptosis as a
function of caspase-3 and -7 activation. Caspase activation
was measured at 24, 48, and 72 h after the six oligonucleo-
tides were transfected into 15PC3 cells at concentrations of
0.2, 1, 5, and 25 nmol/L (Fig. 3). Cells treated with
transfection medium without oligonucleotide were used
as a reference. SPC3042 was the only oligonucleotide that
effectively activated caspases. Treatment with 5 and 25
nmol/L SPC3042 led to programmed cell death that peaked
after 48 h (12-fold activation at 25 nmol/L), and pro-
nounced cell death occurred after 72 h leading to reduction
in the detection of caspase activation (Fig. 3). The
proapoptotic activity of SPC3042 could be observed at a
concentration of 5 nmol/L. Despite being the most potent,
survivin inhibitor SPC2822 showed only slight apoptosis
induction at 25 nmol/L. Minimal activation is also seen for
the control oligonucleotide SPC3046 (Fig. 3). Oligonucleo-
tides with 2¶-O -MOE substitutions (3042MOE and
ISIS23722) and the all phosphorothioate modified
(SPC2823) showed no induction of apoptosis at 25 nmol/
L, and even at concentrations as high as 500 nmol/L, no
significant induction was observed (data not shown). The
induction of apoptosis was confirmed by the Annexin V
staining of cells treated with SPC3042 and SPC3046 (data
not shown).
The lack of caspase activation by the LNA version of
ISIS23722 (SPC2822) indicates that the strong caspase
activation observed for SPC3042 might be a combined
effect of the high survivin target potency and a non-
sequence-specific effect based on the particular sequence.
Figure 1. Properties of oligonucleotides. All oligonucleotides in the study are fully phosphorothiolated. Bold capital letters, LNA modifications; capital
italic letters, 2¶-O -MOE modifications; lowercase letters, DNA. The Tm of the oligonucleotides was determined against their cRNA sequences Tm (jC). The
approximate IC50 values of each oligonucleotide are shown at 24, 48, and 72 h. Both 2¶-O-MOE and LNA nucleotides protect almost entirely SPC3042,
ISIS23722, SPC2822, and 3042MOE against nucleolytic degradation in mouse plasma.
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A general ‘‘LNA effect’’ can be ruled out, because neither
SPC2822 nor SPC3046 is reactive.
Cell CycleArrest
We then studied the cell cycle following survivin
down-regulation (1, 15, 18, 38, 39) for the oligonucleo-
tides described here. To this point, only ISIS23722 has
been noted to confer cell cycle arrest (in G2-M; ref. 24).
Propidium iodide staining of the 15PC3 cells was used
to asses cell cycle arrest and was measured 24, 48, and
72 h post-transfection with 5 nmol/L oligonucleotide.
Cellular staining was analyzed by flow cytometry
(fluorescence-activated cell sorting). SPC2822 showed
significant cell cycle arrest during the entire period,
whereas LY2181308/ISIS23722 arrested the cells only
slightly at 24 h with a minor shift toward the G2-M
phase (Fig. 4A and B).
The 3042MOE and the control SPC3046 did not alter the
proportion of cells in the various phases of the cell cycle
and gave rise to identical histograms as the mock-treated
cells (Fig. 4A). However, cells transfected with SPC3042
revealed, after 24 h, an increase in cells in the G2-M phase
(Fig. 4A). The fraction of cells in the sub-G1 peak seen at the
48 h time point in cells treated with the control SPC3046
was not consequently observed in repeated experiments.
LY2181308/ISIS23722 and 3042MOE have much lower
potency than SPC3042 and SPC2822, and to compensate
this, the concentration was increased to 100 nmol/L. At this
concentration, LY2181308/ISIS23722 arrested cells in the
Table 1. Effect on survivin protein of the oligonucleotides
Oligonucleotide Survivin protein inhibition (% inhibition F SD relative to mock)
1 nmol/L 5 nmol/L 100 nmol/L 500 nmol/L
SPC3042 0 F 9 40 F 3 ND ND
3042MOE 0 F 5 0 F 18 30 F 2 50 F 1
SPC2822 80 F 1 85 F 1 ND ND
LY2181308/ISIS 23722 0 F 10 0 F 2 0 F 2 20 F 4
SPC3046 ND 0 F 15 ND ND
NOTE: 15PC3 cells were treated with the oligonucleotides for 24 h before harvesting and survivin protein was analyzed by ELISA. ND, not determined.
Figure 2. Survivin mRNA. Survivin mRNA inhibition (normalized to mock control) in 15PC3 cells at 24 h post-transfection. Mean of three independent
in vitro transfections with 1, 5, 12.5, 25, 100, and 250 nmol/L concentration of antisense oligonucleotides. Mock represents saline-treated cells. Bars, SD.
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G2-M phase to a similar extent as did SPC2822 at a 20-fold
lower concentration (5 nmol/L). Both SPC2822 (5 nmol/L)
and LY2181308/ISIS23722 (100 nmol/L) halted mitosis and
led to accumulation of chromosomes over a 72 h period
(Fig. 4A). This was confirmed by 4¶,6-diamidino-2-phenyl-
indole staining, which showed multinucleated cells.
SPC3042 Inhibits Bcl-2 Selectively
The data presented above show that down-regulation of
Survivin by the selected oligonucleotides produced diffe-
rent cellular responses including the induction of apoptosis
(SPC3042). To understand the reason for this phenotype,
we examined the effects of the oligonucleotides against
other targets. We showed that SPC3042 also down-
regulated the Bcl-2 mRNA in a dose-dependent manner
(Fig. 5). Other Bcl-2 family members, like Bcl-x, were not
affected (data not shown). The effect on Bcl-2 mRNA was
not linked to survivin down-regulation, because neither
SPC2822, LY2181308/ISIS23722, nor the published anti-
survivin proapoptotic small interfering RNA (siRNA_S1;
ref. 15) had any effect on Bcl-2 expression even at
concentrations of 250 nmol/L (data not shown). The control
oligonucleotide SPC3046 did not produce an effect on Bcl-2
mRNA expression at the doses where SPC3042 was active
(data not shown).
This effect on Bcl-2 was thus related to the specific
sequence of SPC3042, and the observation that the less
potent 3042MOE at higher concentrations (>25 nmol/L)
also down-regulated Bcl-2 mRNA expression supported
this hypothesis (Fig. 5). Furthermore, although this effect is
solely linked to the sequence, it is not linked to the chemical
modifications employed (LNA versus MOE). Bcl-2 inhibi-
tion was confirmed at protein level by Western blotting.
The SPC3042 sequence does not hybridize to the Bcl-2
mRNA by Watson-Crick hybridization. The closest match-
ing complementarities of SPC3042 to the Bcl-2 mRNA
sequence has a Tm below 25jC.
Sensitizing for Taxol
Studies have shown that down-regulation of Survivin
sensitizes cancer cells to chemotherapeutic agents (40, 41).
Having identified SPC3042 as a potent survivin inhibitor
that is associated with the induction of apoptosis, it was
of interest to determine if this agent also sensitized cancer
cells toward Taxol. This mitotic spindle inhibitor has
been reported to synergize with survivin down-regulation
(42, 43).
We used the induction of apoptosis as a measure of a
synergistic effect in 15PC3 cells (Fig. 6A). Taxol (10 nmol/L)
produced no significant induction of apoptosis, but
SPC3042 (10 nmol/L) produced a 6-fold increase in
caspase-3/7 activation (after 48 h). However, in combina-
tion, a 10-fold increase was observed (Fig. 6A). It could also
be detected that the number of cells blocked in the G2-M
phase of the cell cycle was significantly increased when
SPC3042 was combined with Taxol (data not shown).
In vivo Tumor Response
Based on the cellular responses with SPC3042, the in vivo
properties of SPC3042 were examined in combination
with Taxol in a PC3 prostate cancer xenograft mouse
model (Fig. 6B). Animals were treated with either saline,
Taxol, SPC3042, or Taxol and SPC3042. Animals treated
Figure 3. Apoptosis induction. Induction of caspase-3/7 after transfection of 0.2, 1, 5, and 25 nmol/L oligonucleotide. Data are presented as fold
induction of caspase-3/7 relative to mock control. At each concentration, three columns represent data collected at 24 h (left) , 48 h (middle), and 72 h
(right ).
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Figure 4. A and B, fluorescence-activated cell sorting analysis of the cell cycle distribution. Propidium iodide-stained cells. The cell cycle is measured by
and fluorescence-activated cell sorting. Data are collected from oligonucleotides transfected 15PC3 cells at 24, 48, and 72 h. Each peak represents
accumulation of cells within different phases of the cell cycle (see B). The results show cell counts (5,000 cells per sample) as a function of chromosomal
mass. B, fluorescence-activated cell sorting analysis illustration. Schematic presentation of cells analyzed by fluorescence-activated cell sorting after
propidium iodide staining. The different phases of the cell cycle are depicted (G1, S, G2-M, and >G2-M). The >G2-M represents cells that have more than
two sets of chromosomes. Normal distribution of 15PC3 cells at 24 h.
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with Taxol were dosed (10 mg/kg i.p.) on days 8, 14, and 22
with or without SPC3042. Animals treated with SPC3042
were dosed (20 mg/kg i.p.) on days 5, 6, 7, 8, 10, 12, 14, 16,
18, 20, 22, and 24. Compared with saline, animals treated
with Taxol and SPC3042 alone had a marginal reduction in
the tumor weights. However, a significant reduction in
tumor weight was observed in the animals with combined
Taxol and SPC3042 treatment (P < 0.001; Fig. 6B). This
shows the synergistic effect of the Taxol/SCP3042 combi-
nation. The compounds, either alone or in combination,
were well tolerated by the mice. No adverse effects, as
measured by body weight loss and macroscopic autopsy,
were detected.
Discussion
It is well established that LNA can improve the potency
and efficacy of antisense oligonucleotides (44). Thus,
SPC3042 was identified with the purpose of finding more
potent survivin inhibitor. In this study, we compare
isosequential LNAs with 2¶-O-MOE oligonucleotides and
show that they have significantly better potency (Figs. 1
and 2). All oligonucleotides tested, except SPC2823, are
nuclease resistant, so the increased potency is directly
driven by the better affinity provided by LNA. However,
affinity is not the only driver, because SPC2822, which has
a lower Tm compared with SPC3042, has higher potency.
This indicates that other factors, such as target accessibility
on the mRNA, and perhaps the rate of RNase H
recruitment, are of importance as well. For a specific
sequence, the affinity is decisive, and this is why an
isomodified sequence with either LNA or 2¶-O-MOE will
favor the LNA with respect to potency. Although the target
site for SPC3042 is less accessible than the target site for
SPC2822, the high affinity of SPC3042 compensates to a
certain extent. This is illustrated by the fact that SPC3042
has a 5-fold higher IC50 value (at 48 h) for that target site
compared with SPC2822, but for the corresponding 2¶-O-
MOE oligonucleotides the IC50 increase is larger than
10-fold (48 h). This suggests that LNA oligonucleotides will
be able to address many more target sites on the mRNA
with high potency compared with, for example, 2¶-O-MOE
or 2¶-O-Me modified oligonucleotides.
Survivin plays an important role in the control of
apoptosis (1, 4, 5, 41, 43, 45, 46), and we show here that
the survivin inhibitor SPC3042 has strong proapoptotic
activity in cancer cells. This was shown by potent induction
of caspase-3 and -7 activation that peaked at about 48 h after
treatment. However, SPC2822 and its 2¶-MOE analogue,
which also inhibit the expression of survivin, did not
induce apoptosis. The apoptotic phenotype was not related
to the LNA modification per se because neither SPC2822
nor the 16-mer scrambled control SPC3046 (Fig. 3) induced
apoptosis. Likewise, it was found that none of the 2¶-O-
MOE-modified oligonucleotides elicited apoptosis in con-
centrations comparable with SPC3042.
The nonapoptotic survivin inhibitors arrested the cells
predominantly in the G2-M phase of the cell cycle.
However, the irreversible apoptotic pathway, which is
induced by SPC3042, could scatter the observations of cell
cycle arrest simply because the arrested cells are dying.
The difference in proapoptotic activity was not found to
be due to differences in the survivin splice variant
expression profile (data not shown). Surprisingly however,
we found that Bcl-2 mRNA and protein was down-
regulated after treatment with SPC3042. This effect cannot
be caused by an antisense effect via Watson-Crick
hybridization because there is no sequence homology
Figure 5. Bcl-2 mRNA. Bcl-2 mRNA inhibi-
tion (normalized to mock control) in 15PC3
cells at 24 h post-transfection. Mean of three
independent transfections using 1, 5, 12.5,
25, 100, and 250 nmol/L oligonucleotide.
Bars, SD.
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between SPC3042 and Bcl-2. Furthermore, basic Local
Alignment Search Tool studies of the SPC3042 sequence
did not provide additional RNA or DNA targets for
SPC3042. However, the effect was related to the specific
sequence of SPC3042, because the less potent 2¶-O-MOE
variant at higher concentrations (>100 nmol/L) also down-
regulated Bcl-2 expression.
A link between transcription control of survivin and Bcl-2
is not evident, so we anticipate that the observed effect
on the Bcl-2 transcript is not a direct result of survivin
inhibition. The mechanism behind this is currently uncer-
tain, but evidently it is related to the specific sequence of
SPC3042. Irrespective of the molecular mechanism, the
marked proapoptotic phenotype of SPC3042 is likely to be a
combination of multiple effects.
LY2181308/ISIS23722 has been tested in antitumor
models. It has been administrated intratumorally into
xenografted human tumor cells or pretransfected into cells
before transplantation (19), and antitumor responses have
been observed. However, the effects on tumors, following
systemically administration of this drug, have not yet been
published.
Because survivin inhibitors are known to synergize with
Taxol in antitumor models, we evaluated if the potent
inhibition of survivin by SPC3042 could lead to the same
effect following systemically administration.
We evaluated SPC3042 in combination with Taxol in the
15PC3 prostate cancer cell line and found that adding Taxol
to SPC3042-treated cells increased the induction of caspase-
3/7 by 2-fold. The administered 20 mg/kg SPC3042 (i.p.)
combined with 10 mg/kg Taxol to xenografted mice
showed reductions of PC3 tumor weights by 40% com-
pared with the saline control (P < 0.0001; Fig. 6B). Neither
10 mg/kg Taxol nor SPC3042 alone reduced tumor
weights, to any significant effect. These data show that
SPC3042 can significantly reduce tumor growth of prostate
tumors in combination with Taxol and improve the
therapeutic effect of both. SPC3042 has been assessed in
investigational new drug enabling toxicology studies in
rodents and primates. The maximum tolerated dose was
determined in rats and it was found to be >1,000 mg/kg.
A comprehensive presentation of the toxicology is beyond
the scope of this article but will be reported in due course.
We find the antitumor activity and safety encouraging for
further oncologic exploration of SPC3042 in a clinical
setting.
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